Abstract:Objectives/hypothesis: Death-associated protein kinase (DAPK) is a Ca/calmodulin-regulated Ser/Thr kinase that functions as a positive mediator of programmed cell death. It has been found that DAPK gene is frequently inactivated by its promoter hypermethylation in some cancers and tumor cell lines. However, it is not clear whether promoter hypermethylation of DAPK gene exists in laryngeal squamous cell cancer (LSCC). The aim of this study was to investigate the promoter methylation status of the DAPK gene in LSCC and the effect of 5-Aza-2'-deoxycytidine (5-Aza-CdR), a demethylating agent, on Hep-2 cells, a human laryngeal cancer cell line, and on xenografts of Hep-2. Methods: Methylation-specific polymerase chain reaction (PCR) and reverse-transcription PCR techniques were used to determine the promoter methylation status and mRNA expression of DAPK gene in LSCC. Furthermore, Hep-2 cells in vitro and in vivo were treated by 5-Aza-CdR to explore the effect of demethylating agents on DAPK mRNA expression and tumor growth. Results: Hypermethylation of DAPK gene promoter was found in 39 (67.2%) of 58 LSCC samples. There was no significant difference in the promoter hypermethylation rate among the samples of different histologic grades or samples from patients with different T stages. However, there was significant difference in methylation status of DAPK gene between the samples from patients in N0 stages and those from patients in N1 stages. No promoter hypermethylation of DAPK gene was found in any of the five normal laryngeal tissue samples. DAPK mRNA expression was not detected in tumor specimens with promoter hypermethylation. On the contrary, DAPK mRNA expression was observed in the unmethylated tumor specimens, specimens from tissues adjacent to the tumor, and normal laryngeal tissues samples. Promoter hypermethylation of DAPK gene was found, and no DAPK mRNA expression was detected in Hep-2 cells. DAPK mRNA expression in Hep-2 cells and xenografts could be restored by treating cells and xenografts with 5-Aza-CdR. The tumors' xenografts, induced by way of Hep-2 cell injection in nude mice treated with 5-Aza-CdR, were obviously smaller than those in nude mice treated with phosphate-buffered saline. Conclusions: Abnormal loss of DAPK expression could be associated with aberrant promoter region methylation in the LSCC. 5-Aza-CdR may slow the growth of Hep-2 cells in vitro and in vivo by reactivating tumor suppressor gene DAPK silenced by de novo methylation.

Expression of Cby and Methylation of Cby at Promoter Region in Human Laryngeal Squamous Cell Carcinoma

Downregulated Chibby in laryngeal squamous cell carcinoma with increased expression in laryngeal carcinoma Hep-2 cells.

Clinical Significance of Methylation of E-cadherin and P14arf Gene Promoters in Skin Squamous Cell Carcinoma Tissues.

Methylation Status of the Long Control Region of Hpv 16 in Clinical Cervical Specimens

Epigenetic identification of CHD5 as a critical 1p36.3 tumor suppressor frequently inactivated by promoter methylation in multiple carcinomas

Epigenetic Inactivation of Bcl6b, A Novel Functional Tumour Suppressor for Gastric Cancer, is Associated with Poor Survival

LMX1B mRNA expression and its gene body CpG methylation are valuable prognostic biomarkers for laryngeal squamous cell carcinoma

The expression of thrombospondin 1 and its gene hypermethylation in laryngeal squamous cell cancer

Downregulation of Thrombospondin-1 by DNA Hypermethylation is Associated with Tumor Progression in Laryngeal Squamous Cell Carcinoma.

INFREQUENTLY METHYLATED EVENT AT SITES −181 TO −9 WITHIN THE 5′ CpG ISLAND OF<i>E-CADHERIN</i>IN NON-SMALL CELL LUNG CANCER

Aberrant Methylation of the SOX21-AS1 Promoter Region Promotes Gene Expression and Its Clinical Value in Cervical Cancer

Methylation-associated silencing of death-associated protein kinase gene in laryngeal squamous cell cancer

Promoter Methylation-Mediated Silencing of β-Catenin Enhances Invasiveness of Non-Small Cell Lung Cancer and Predicts Adverse Prognosis

Decreased 5-Hydroxymethylcytosine (5-Hmc) Predicts Poor Prognosis in Early-Stage Laryngeal Squamous Cell Carcinoma.

Methylation of LAPTM4B Promoter Region Influences Its mRNA Expression in Esophageal Cancer

The Silencing Of Ccnd2 By Promoter Aberrant Methylation In Renal Cell Cancer And Analysis Of The Correlation Between Ccnd2 Methylation Status And Clinical Features

Clinical outcomes of downregulation of E-cadherin gene expression in non-small cell lung cancer.

Analysis of Promoter Methylation of DBCCR1 Gene in Bladder Transitional Cell Carcinoma

Epigenetic Silencing of the 3p22 Tumor Suppressor DLEC1 by Promoter CpG Methylation in Non-Hodgkin and Hodgkin Lymphomas

Genome-wide Analysis of DNA Methylation in Tongue Squamous Cell Carcinoma

Aberrant Hypermethylation at Sites -86 to 226 of DAB2 Gene in Non-Small Cell Lung Cancer